Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies

Modern Pathology

Volumn 30, Issue 12, 2017, Pages 1739-1747

  Gaut, Joseph P ^a   Jain, Sanjay ^a   Pfeifer, John D ^a   Vigh Conrad, Katinka A ^a   Corliss, Meagan ^a   Sharma, Mukesh K ^a   Heusel, Jonathan W ^a   Cottrell, Catherine E ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C3 PROTEIN; CFB PROTEIN; CFH PROTEIN; CFI PROTEIN; DGKE PROTEIN; MEMBRANE COFACTOR PROTEIN; PROTEIN; THBD PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CODING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EXOME; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; AGED; CASE CONTROL STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PROCEDURES;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; EXOME; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; THROMBOTIC MICROANGIOPATHIES;

EID: 85037040858     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2017.90     Document Type: Article

References (46)

1. Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol 2015;67:31-42.
2. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654-666.
3. Bu F, Borsa NG, Jones MB, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 2016;27: 1245-1253.
4. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-1859.
5. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:1676-1687.
6. Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr 2014;61:335-356.
7. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013;8: 554-562.
8. Bu F, Borsa N, Gianluigi A et al. Familial atypical hemolytic uremic syndrome: A review of its genetic and clinical aspects. Clin Dev Immunol 2012;2012:370426.
9. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013;33: 508-530.
10. Stokman MF, Renkema KY, Giles RH, et al. The expanding phenotypic spectra of kidney diseases: insights from genetic studies. Nat Rev Nephrol 2016;12:472-483.
11. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 2016;12:133-146.
12. Prakash S, Gharavi AG. Diagnosing kidney disease in the genetic era. Curr Opin Nephrol Hypertens 2015;24: 380-387.
13. Fakhouri F, Fila M, Provot F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 2016;12:50-59.
14. Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25:55-64.
15. Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010;148:37-47.
16. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35: 421-447.
17. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016;31:15-39.
18. Wetterstrand K. Sequencing costs: data from the NHGRI genome sequencing program (GSP). Available at: https://www. genome. gov/sequencingcostsdata/ (last accessed 9 August 2016).
19. Braun DA, Schueler M, Halbritter J, et al. Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhoodonset increased renal echogenicity. Kidney Int 2016;89: 468-475.
20. Mori T, Hosomichi K, Chiga M, et al. Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel. Clin Exp Nephrol 2016;21:63-75.
21. Moriniere V, Dahan K, Hilbert P, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 2014;25:2740-2751.
22. Chatterjee R, Ramos E, Hoffman M, et al. Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations. Hum Genet 2012;131: 1725-1738.
23. Liapis H, Jain S. The interface of genetics with pathology in alport nephritis. J Am Soc Nephrol 2013;24:1925-1927.
24. Maga TK, Nishimura CJ, Weaver AE et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010;31:E1445-E1460.
25. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424.
26. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
27. Moore I, Strain L, Pappworth I, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010;115: 379-387.
28. Aziz N, Zhao Q, Bry L, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 2015;139:481-493.
29. Sharma MK, Phillips J, Agarwal S, et al. Clinical genomicist workstation. AMIA Jt Summits Transl Sci Proc 2013;2013:156-157.
30. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60, 706 humans. Nature 2016;536:285-291.
31. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 2011;27:2987-2993.
32. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-2079.
33. Davydov EV, Goode DL, Sirota M, et al. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 2010;6:e1001025.
34. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 2012;7:e46688.
35. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003;12:3385-3395.
36. Mohlin FC, Nilsson SC, Levart TK, et al. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol 2015;65:367-376.
37. Neumann HP, Salzmann M, Bohnert-Iwan B, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J Med Genet 2003;40:676-681.
38. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001;68:478-484.
39. Sartz L, Olin AI, Kristoffersson AC, et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012;188:2030-2037.
40. Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8:1694-1701.
41. Bienaime F, Dragon-Durey MA, Regnier CH, et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010;77:339-349.
42. Schramm EC, Roumenina LT, Rybkine T, et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 2015;125:2359-2369.
43. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009;361:345-357.
44. Lemaire M, Fremeaux-Bacchi V, Schaefer F, et al. Recessive mutations in DGKE cause atypical hemolyticuremic syndrome. Nat Genet 2013;45:531-536.
45. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-563.
46. Chong JX, Buckingham KJ, Jhangiani SN, et al. The genetic basis of mendelian phenotypes: discoveries, challenges, and opportunities. Am J Hum Genet 2015;97:199-215.